Valuation: Bioventix PLC

Market Cap 10Cr 14Cr 12Cr 11Cr 19Cr 1.28TCr 20Cr 134.53Cr 54Cr 682.97Cr 51Cr 50Cr 2.16TCr P/E 2026
11.5x
P/E 2027 * 13.6x
Enterprise Value 9.7Cr 13Cr 12Cr 11Cr 18Cr 1.22TCr 19Cr 128.06Cr 51Cr 650.12Cr 49Cr 48Cr 2.05TCr EV / Sales 2026
6.24x
EV / Sales 2027 * 7.5x
Free-Float
92.29%
Yield 2026
9.09%
Yield 2027 * 7.69%
1 day+1.04%
1 week-2.50%
Current month-2.50%
1 month+11.43%
3 months+29.14%
6 months+14.71%
Current year+2.36%
1 week 1,850
Extreme 1850
2,120
1 month 1,650
Extreme 1650
2,120
Current year 1,300
Extreme 1300
2,120
1 year 1,300
Extreme 1300
2,255
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 23/12/2003
Director of Finance/CFO 67 01/07/2020
Director TitleAgeSince
Director/Board Member 67 25/11/2010
Chairman 66 01/11/2004
Director/Board Member 67 01/07/2020
Date Insider Type Main position Quantity % Market Cap. Importance
28/04/26 Buy

Chief Financial Officer

66 0.0013%
20/04/26 Free

Chief Executive Officer

9,967 0.1908%
20/04/26 Free

Chief Financial Officer

9,967 0.1908%
Change 5-day change 1-year change 3-year change Capi.($)
+1.04%-2.50%-8.24%-47.30% 14Cr
-4.83%+3.51%+55.00%+63.79% 6.67TCr
+0.02%+1.07%+11.72%+75.63% 5.69TCr
-1.34%+2.98%+25.08%+100.18% 5.65TCr
+5.09%+9.89%+27.19%+105.85% 4.65TCr
+2.62%+1.68%+29.16%+35.86% 4.48TCr
+8.24%+0.51%+215.16%+794.74% 4.16TCr
-1.86%+10.13%+28.14%+55.48% 3.53TCr
-2.97%-9.84%+90.91%+73.49% 3.33TCr
+5.19%+1.62%-39.69%+368.87% 2.51TCr
Average +1.12%+2.13%+43.44%+162.66% 4.07TCr
Weighted average by Cap. +0.65%+3.07%+49.88%+165.80%

Financials

2026 2027 *
Net sales 1.25Cr 1.67Cr 1.5Cr 1.37Cr 2.36Cr 157.04Cr 2.43Cr 17Cr 6.58Cr 84Cr 6.27Cr 6.14Cr 264.52Cr 1.3Cr 1.73Cr 1.55Cr 1.42Cr 2.44Cr 162.82Cr 2.52Cr 17Cr 6.82Cr 87Cr 6.5Cr 6.36Cr 274.26Cr
Net income 71L 94.89L 85.11L 77.78L 1.34Cr 89Cr 1.38Cr 9.38Cr 3.74Cr 48Cr 3.56Cr 3.49Cr 150.25Cr 75.06L 1Cr 89.97L 82.23L 1.41Cr 94Cr 1.46Cr 9.91Cr 3.95Cr 50Cr 3.77Cr 3.68Cr 158.84Cr
Net Debt -49L -65.49L -58.73L -53.68L -92.32L -62Cr -95.23L -6.47Cr -2.58Cr -33Cr -2.46Cr -2.41Cr -103.69Cr -46.25L -61.81L -55.44L -50.67L -87.14L -58Cr -89.89L -6.11Cr -2.44Cr -31Cr -2.32Cr -2.27Cr -98Cr
Projected Income Statement - Annual - Bioventix PLC
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
12
Date Price Change Volume
06/26/06 GBX 1,950.00 +1.04% 9,698
05/26/05 GBX 1,930.00 -4.69% 1,57,504
04/26/04 GBX 2,025.00 -1.22% 13,348
03/26/03 GBX 2,050.00 0.00% 15,781
02/26/02 GBX 2,050.00 +2.50% 14,183
Trader
Investor
-
Global
-
Quality
ESG MSCI
CCC
MarketScreener Ratings - Bioventix PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
19.50GBP
Average target price
39.00GBP
Spread / Average Target
+100.00%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Bioventix PLC
  1. Stock Market
  2. Stocks
  3. BVXP Stock